News: Approval of moxidectin for a pilot onchocerciasis community treatment programme in Ghana

In December 2024, Medicines Development for Global Health (MDGH) – a not-for-profit pharmaceutical company – announced that the Ghana Food and Drugs Authority had authorised the use of moxidectin 2mg oral tablets for the treatment of onchocerciasis in adults and children aged 4 years and older.1 This announcement declared Ghana the first onchocerciasis-endemic country to receive regulatory approval for moxidectin, marking an important step towards elimination goals and allowing the commencement of a pilot community treatment programme, the Momentum Project.